SecBot SecBot
8-K ·Filed Jul 14, 2026

ERAS

Erasca, Inc.
MIXED
Impact 6/10
Horizonimmediate Processed4mo ago SEC0001193125-26-303357
8-K context-dependent: Items 8.01
Actionable Insight ◆ Mixed

The offering provides significant cash runway for Erasca's pipeline development but dilutes existing holders by ~10%. Monitor for upcoming clinical data catalysts that could justify the dilution; the upsized offering suggests strong institutional demand, which may support the stock near the $17.50 offering price in the near term.

DirectionMixed
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$21.26
T+0 close · Jul 14, 2026 · via day close
Latest settled
−27.28%
T+60 · $15.46
Vs SPY
−29.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $21.26entry
  2. T+1 · 4mo ago −10.54%α −9.99% · $19.02
  3. T+5 · 4mo ago −8.23%α −7.25% · $19.51
  4. T+20 · 3mo ago −12.61%α −14.95% · $18.58
  5. T+60 · 6w ago −27.28%α −29.81% · $15.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca priced an upsized public offering of 31,428,572 shares at $17.50 per share, raising approximately $516 million in net proceeds ($593.5 million if the underwriters' option is exercised in full). The offering provides substantial cash to fund its RAS/MAPK pipeline and general corporate purposes, but dilutes existing shareholders by roughly 10%. The upsized size signals strong institutional demand, partially offsetting dilution concerns.

Key Facts

  • Erasca priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share.
  • Net proceeds expected to be approximately $516.0 million, or $593.5 million if the underwriters' 30-day option to purchase an additional 4,714,285 shares is exercised in full.
  • Underwriters purchase price is $16.45 per share; offering expected to close July 15, 2026.
  • Proceeds will be used to fund research and development of product candidates and other development programs, working capital, and general corporate purposes.
  • The offering was upsized from the initially proposed $500 million to $550 million in gross proceeds.

Financial Impact

Dilution of approximately 9-11% based on current market cap of $5.6B; cash infusion of ~$516M net ($593.5M with option).

dilutioncash

Risk Factors

  • Dilution of approximately 9-11% from the new shares.
  • Potential overhang from the underwriters' option to purchase additional shares.
  • Clinical-stage biotech risk: no approved products; pipeline execution is key.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-303357
Document: d371010d8k.htm0001193125-26-303357
Document: d371010dex51.htm0001193125-26-303357
Document: d371010dex992.htm0001193125-26-303357
Document: d371010dex991.htm0001193125-26-303357
Document: 0001193125-26-303357-index-headers.html0001193125-26-303357
Document: 0001193125-26-303357-index.html0001193125-26-303357
Document: 0001193125-26-303357.txt0001193125-26-303357

Track record

26 reports on ERAS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026